Growing scope of Genetic Medicine and Stem Cell Research – The Hindu

Various career paths are available in the field of Genetic Medicine and Stem Cell Research Various career paths are available in the field of Genetic Medicine and Stem Cell Research

Among the various streams of science and medicine that have evolved with time, stem cell research and genetic medicine have risen as top contenders for various path-breaking discoveries. The treatment of more than 1,800 known monogenic hereditary disorders today, depends on the development of genetic medicines coupled with advanced stem cell research.

The field of genetic medicine comprises many areas, including the clinical practice of physicians, genetic counsellors and nutritionists, clinical diagnostic laboratory activities, and research into the causes and inheritance of genetic disorders. Simply put, it incorporates areas such as gene therapy, personalised medicine, and the rapidly emerging new medical speciality, including predictive medicine.

Stem cells are basically adaptable and versatile cells in ones body that are capable of complex actions, unlike conventional medication. These cells exist both in embryos and adult cells and can differentiate into any cell of an organism with the ability of self-renewal. Stem cell therapy uses these cells to treat or prevent a disease or condition. Also known as regenerative medicine, it promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

Amid a prevailing global healthcare crisis, stem cell research and genetic medicine have given us hope. The former was and continues to be an integral part of research conducted to treat COVID-19 symptoms, and genome sequencing has been extensively employed globally to analyse mutations and variations of the virus. In the coming years, the industry is only expected to grow.

Also, there is a general misconception that only people with medical education can take up jobs in these fields. This is not completely true because students who have studied Biology, B.Sc. graduates with at least one subject of the Biological Sciences, MBBS, B.Pharma, B.D.S., B.V.Sc. or B.E. Biotechnology students are eligible too.

Possible career options include Clinical geneticist, Genetic Counsellor, Clinical Researcher, Research Scientist, Biochemical Diagnostics Professional, Biomedical Research Assistant, Biomedical Technician, Cancer Research Scientist, Biomedical Engineer, Molecular Genetics Professional, Laboratory Technician, and Laboratory Director.

The writer is Senior Medical Director - LifeCell.

Excerpt from:
Growing scope of Genetic Medicine and Stem Cell Research - The Hindu

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types…

Sana Biotechnology, Inc

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression

The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model

Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward development of engineered cells for the treatment of disease

SEATTLE, June 17, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data showing survival of transplanted allogeneic, hypoimmune cells of several different types in a variety of locations in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cell (iPSC)-derived cardiomyocytes, retinal pigment epithelium (RPE) cells, and islet cells, which were engineered to include Sanas hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during sessions at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.

These data, demonstrating that three types of transplanted cells are able to survive and function in NHPs without immunosuppression, highlight the transformative potential of Sanas hypoimmune platform across a number of different cell types that can address a variety of diseases, said Steve Harr, Sanas President and Chief Executive Officer. As an example, the use of allogeneic islet transplant has had limited success in treating type 1 diabetes due to morbidities from the necessary immunosuppression. In contrast, our data indicate that we successfully engineered HIP human pancreatic islet cells to evade immune recognition, and these cells persisted and normalized glucose levels in in vivo models. We are applying the hypoimmune platform to a number of programs in our pipeline, including SC291, our CD19 targeted allogeneic CAR T therapy for blood cancers, with a goal of an IND this year, and SC451, our islet cell program with a goal of an IND for the treatment of type 1 diabetes in 2023.

Story continues

Transplanting cells or tissues from a donor to a different recipient currently requires intense immunosuppression to prevent rejection of the transplant. Sanas HIP platform goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition. The platform includes disruption of the major histocompatibility (MHC) class I and MHC class II expression to hide cells from the adaptive immune system, which includes antibody and T cell responses. These changes alone make cells susceptible to innate immune cell killing, in particular by natural killer (NK) cells. However, Sanas HIP platform additionally provides for evasion from innate cell killing, including via the overexpression of CD47, a molecule that protects HIP-modified cells from innate cell killing involving either NK cells or macrophages. HIP-modified pluripotent stem cells can serve as the starting material for the differentiation of specialized cell types to serve as cell-based therapeutics. Sanas goal is to use these HIP-modified cells to replace damaged or missing cells in the body in a number of different diseases, including, among others, cancer, type 1 diabetes, and cardiac disease.

Survival of HIP-modified islet cells for type 1 diabetes

Primary NHP pancreatic islet cells In this study, allogeneic primary pancreatic islet cells were HIP edited and transplanted intramuscularly into a healthy NHP without immunosuppression (n=1) as proof-of-concept. Islet cell survival was followed by in vivo bioluminescence imaging. The imaging showed that transplanted cells survived for the duration of the study (three months at data lock) with no evidence of a systemic immune response, including no T cell activation, antibody production, or NK cell activity as seen previously with other HIP edited cell types in NHPs (iPSC, cardiomyocytes, and RPE). Allogeneic unmodified primary pancreatic islet cells disappeared rapidly within 2 weeks.

Autoimmune mice Type 1 diabetes is a disease in which the patients immune system attacks and kills their pancreatic beta cells. Therefore, allogeneic transplanted cells in type 1 diabetes need to overcome both allogeneic and autoimmune rejection. Autoimmune diabetes arises spontaneously in non-obese diabetic (NOD) mice, and the pathophysiology of this disease shares many similarities with human type 1 diabetes. Since its development in 1980, this model has represented the gold standard of spontaneous disease models, allowing for investigation of autoimmune diabetes disease progression and susceptibility traits, as well as to test a wide array of potential treatments and therapies.

In this study, syngeneic or allogeneic mouse islet cells were transplanted intramuscularly without immunosuppression into diabetic autoimmune mice (n=15), split into three cohorts. The first cohort received unmodified syngeneic islet cells, the second cohort received unmodified allogeneic islet cells, and the third cohort received allogeneic HIP islet cells. The unmodified cells disappeared rapidly in the allogeneic setting (within 10 days) as well as in the syngeneic setting (within two weeks) due to autoimmune recognition. Neither cohort had a decrease in glucose levels. The HIP islet cells survived in all five diabetic mice for the duration of the study (one month at data lock), and glucose levels dropped, demonstrating therapeutic function of the HIP islet cells.

Survival of HIP-modified cardiomyocytes (iPSC-derived) In this study, allogeneic iPSC-derived cardiomyocytes were transplanted without immunosuppression into the hearts of healthy NHPs split into two cohorts. The first cohort received unmodified allogeneic iPSC-derived cardiomyocytes (WT; n=2), while the second cohort received allogeneic HIP iPSC-derived cardiomyocytes (HIP; n=4). The unmodified cells were almost eliminated in all NHPs, with significant T cell activation in addition to antibody production and binding. The HIP cardiomyocytes survived in all four monkeys for the duration of the study (up to two months at data lock), and there was no evidence of a systemic immune response, including no T cell activation, antibody production, or NK cell activity. After two months, injection sites were recovered, and local immune cells were analyzed for their donor-specific cell recognition and killing. While local immune cells kill unmodified cardiomyocytes, HIP cardiomyocytes were not recognized by these immune cells.

Survival of HIP-modified retinal pigmental epithelial (RPE) cells (iPSC-derived) In this study, allogeneic iPSC-derived RPEs were transplanted into the eye of healthy NHPs without immunosuppression split into two cohorts. The first cohort received unmodified allogeneic iPSC-derived RPE (WT; n=3), while the second cohort received allogeneic HIP iPSC-derived RPE (HIP; n=3). The unmodified cells were almost completely eliminated in all NHPs within three weeks, with significant T cell activation, antibody production and local microglial activation, demonstrating in this context that the eye is not an immunoprivileged site.

The HIP RPE survived in all three monkeys for the duration of the study (three weeks at data lock), and there was no evidence of a systemic immune response, including no T cell activation, antibody production, microglial or NK cell activity. Two weeks after the initial dose, the NHPs were re-injected with the same cell type into the second eye, so that the NHPs received a total of two doses. Unmodified WT RPEs again evoked a rapid systemic immune response in all NHPs, with activation of T cells and antibody production, and cells almost completely eliminate within one week. HIP RPE cells continued to survive even after re-injection without stimulation of adaptive or innate immune responses. These data suggest the potential to re-administer HIP RPE cells.

Sana intends to submit the data behind its presentations for publication in a peer-reviewed journal.

About Hypoimmune Platform Sanas hypoimmune platform is designed to create cells ex vivo that can hide from the patients immune system to enable the transplant of allogeneic cells without the need for immunosuppression. We are applying the hypoimmune technology to both pluripotent stem cells, which can then be differentiated into multiple cell types, and to donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale. Preclinical data demonstrates across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Our most advanced programs utilizing this platform include an allogeneic CAR T program targeting CD19+ cancers and stem-cell derived beta islet cells for patients with type 1 diabetes.

About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; the potential ability to make allogeneic, hypoimmune cells, including iPSC-derived cardiomyocytes, RPE cells, and islet cells, that survive and evade the immune system without immunosuppression and the potential persistence and efficacy of such hypoimmune cells; and the Companys expectations with respect to the submission and publication of data. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 10, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media: Nicole Keith Investor.relations@sana.com media@sana.com

Link:
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types...

Cell Culture Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2030 – Digital Journal

Cell Culture Market: Introduction

According to the report, the globalcell culture marketwas valued at US$10.5Bn in 2020 and is projected to expand at a CAGR of9%from 2021 to 2031. The global cell culture market is driven by development of new products, technological advancements, and increase in use of single-use bioprocessing systems during the forecast period. The cell culture market in Asia Pacific is anticipated to expand at the fastest CAGR during the forecast period due to high unmet clinical needs, improvements in the healthcare infrastructure, and increase in focus on research & development activities.

Rise in Demand and Approvals for Biosimilar Products & Other Biologic Therapeutics to Drive Market

Cell culture is one of the most important steps for the production of biosimilar antibodies, as cell culture helps increase efficiency & productivity and reduce the cost of manufacture. The increase in demand & approvals for biosimilars products and other biologic therapeutics for the treatment of chronic diseases in developed as well as developing countries has led to the demand for efficient and cost-effective products. This is expected to drive the global cell culture market during the forecast period.

Get a sample of the report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405

Moreover, rise in demand for cost-effective and highly efficient cell culture products such as bioreactors, media, reagents, and sera for the production of high-yield cell lines has led to a surge in the number of new product launches. This is likely to provide lucrative opportunities in the global cell culture market during the forecast period. Major manufactures strive to expand their product portfolio by launching new and advanced systems for large-scale production, which is cost-effective and has low risk of contamination.

For instance, in 2018, Merck launched capsule filters that are designed to decrease the risk of contamination in a bioreactor. These filters are used for the separation of mycoplasma and bacteria from cell culture media. However, ethical issues associated with the use of fetal bovine serum, stringent regulations, and high cost of infrastructure for cell culture are projected to hamper the growth of global cell culture market during the forecast period.

Technological Advancements in Cell Culture Production Media & Instruments to Drive Demand for Protein-based Therapeutics

In terms of product, the global cell culture market has been classified into instruments, media, sera, and reagents. The instruments segment has been categorized into cell culture vessels (bioreactors), carbon dioxide incubators, biosafety cabinets, cryogenic tanks, and others. Technological advancements for improving the efficiency and reducing the risk of cross contamination are anticipated to propel the instruments segment during the forecast period.

The media segment has been split into chemically defined, classical media, protein free media, Lysogeny media, serum free media, and specialty media. The efficiency of different media used for cell culture production is expected to drive the media segment over the next few years.

The sera segment has been bifurcated into fetal bovine serum and others. Sera are used as cell culture supplements consisting of growth factors, nutrients, and other important trace elements. The reagents segment has been segregated into albumin, amino acid, attachment factors, growth factors & cytokines, protease inhibitor, thrombin, and others. Applications such as stem cell research have vast potential in future. Stem cell culture assists in standardization of drug production and enables production of a number of cell lines & related products.

Traditional pharmaceutical therapeutics help in treating only disease symptoms, whereas stem cell therapies assist in treating the cause of the disease. Hence, further research in the field of stem cell culture for development of drugs presents significant opportunities in the market in the near future.

Request for Analysis of COVID-19 Impact on Cell Culture Market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=405

Increase in Usage of Cell Culture Products in Drug Development & Manufacturing to Propel Pharmaceutical Companies Segment

Based on end-user, the global cell culture market has been divided into biotechnology companies, pharmaceutical companies, academic institutes, and research institutes. The pharmaceutical companies segment dominated the global market in 2020, and the trend is anticipated to continue during the forecast period due to increase in usage of cell culture products in drug development and manufacturing. The biotechnology companies segment is expected to account for a significant market share by 2031. The growth of the segment can be attributed to increase in the number of biotechnology companies and rise in strategic collaborations among market players to expand global presence.

Asia Pacific to Dominate Global Market

In terms of region, the global cell culture market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a major share of the global market during the forecast period, owing to the presence of key players, increase in research & development activities, and new drug approvals.

Shift in trend toward continuous processing is expected to drive the cell culture market in North America. The cell culture market in Asia Pacific is at a pivotal point. Increase in focus of key players on expansion in the region, large untapped population, and rise in awareness about healthcare augment the cell culture market in Asia Pacific. For instance, Thermo Fisher expanded its Fisher BioServices and cryogenic service capabilities in Japan.

Thermo Fisher Scientific and Merck KGaA to Lead Global Market

Key players covered in this report are Sartorius AG, Thermo Fisher Scientific, Inc., Eppendorf AG, GE Healthcare, Corning Incorporated, Becton, Dickinson and Company, Merck KGaA, Lonza, VWR International, LLC, and PromoCell GmbH. Companies operating in the global cell culture market focus on strategic collaborations for developing new products in the emerging markets such as Asia Pacific and Latin America.

For instance, in May 2017, Merck announced the launch of EX-CELL Advanced HD perfusion medium, which helps increase the production yield and streamline the regulatory compliances.

Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=405

Global Cell Culture Market: Segmentation

Cell Culture Market, by Product

Cell Culture Market, by End-user

More Related Reports by Transparency Market Research

perating Room Equipment Market: https://www.transparencymarketresearch.com/operating-room-equipment-market.html

Arterial Stents Market: https://www.transparencymarketresearch.com/arterial-stents-market.html

Personalized LASIK Surgery Market: https://www.transparencymarketresearch.com/personalized-lasik-surgery-market.html

Anastomosis Devices Market: https://www.transparencymarketresearch.com/anastomosis-devices-market.html

Electrosurgical Devices Market: https://www.transparencymarketresearch.com/electrosurgical-devices-market.html

Life Science Microscopy Devices Market: https://www.transparencymarketresearch.com/life-science-microscopy-devices.html

Ultrasonic Scalpels Market: https://www.transparencymarketresearch.com/ultrasonic-scalpels-market.html

PPE Kit Market: https://www.transparencymarketresearch.com/ppe-kit-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: [emailprotected]

Website: https://www.transparencymarketresearch.com/

See the rest here:
Cell Culture Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2030 - Digital Journal

Stem Cell Cartilage Regeneration Market Strategic Insights of Developing Industry by Top Growing Prominent Players Profile: Anika Therapeutics, Zimmer…

Global Stem Cell Cartilage Regeneration MarketResearch Report provides key analysis on the market status of the Stem Cell Cartilage Regeneration with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report also calculates the market size, Sales, Price, Revenue, Gross Margin, Market Share, cost structure, and growth rate. The report considers the revenue generated from the sales of This Report and technologies by various application segments and Browse Market data Tables.

The Stem Cell Cartilage Regeneration Market report covers the different market scenarios that have a direct impact on the growth of the market. The Stem Cell Cartilage Regeneration report study includes information on market factors such as the market dynamics, including drivers, restraints, challenges, threats, and potential growth opportunities, market trends, development patterns, financial information, latest technologies, innovations, leading competitors, and regional analysis of the market.

RequestMore Information on this Report (UseCorporate eMail ID to Get Higher Priority):https://www.worldwidemarketreports.com/sample/624293

The following Key Players are Mentioned in this Document:

Anika Therapeutics Zimmer Biomet BioTissue Technologies DePuy (Johnson & Johnson) Genzyme CellGenix EMD Serono Sanofi Aventis Smith & Nephew

Analysis ofStem Cell Cartilage RegenerationMarket by Type

Cell Based Approaches Non-cell Based Approaches

Analysis ofStem Cell Cartilage Regeneration Market by Application

Hyaline Cartilage Fibrocartilage Other

Get a Sample to Understand More Details on Stem Cell Cartilage Regeneration Market Segments:https://www.worldwidemarketreports.com/sample/624293

Regional Analysis for Stem Cell Cartilage Regeneration Market:

North America (U.S., Canada) Europe (U.K., Italy, Germany, France, Rest of EU) Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) Latin America (Chile, Brazil, Argentina, Rest of Latin America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

(*NOTE: To get customization to your liking you can ADD / REMOVE Key Players, Regions, and any other Segments as you need.)

How Covid 19 Affected the Stem Cell Cartilage Regeneration Market

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Impact Stem Cell Cartilage Regeneration market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations, travel bans, and quarantines, restaurants closed, all indoor/outdoor events restricted, over forty countries state of emergency declared, massive slowing of the supply chain, stock market volatility, falling business confidence, growing panic among the population, and uncertainty about future.

Get Specified Sample Containing COVID 19 Details:https://www.worldwidemarketreports.com/sample/624293

In this segment, we will give you the impact of COVID-19, how it affected the Stem Cell Cartilage Regeneration market, and how it will change the industrys future depending on the current government, private, and public situations. Our expert analysts keep an open eye on every situation that may change the flow of the industry which will help you make the best possible decision for your enterprise.

The objective of the study is to define the Stem Cell Cartilage Regeneration market sizes of different segments and countries in previous years and to forecast the values for the next five years. The report is designed to incorporate both qualified qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about crucial aspects such as drivers and restraining factors that will define the future growth of the Stem Cell Cartilage Regeneration market.

You can Buy This Report Here:https://www.worldwidemarketreports.com/buy/624293

Report Coverage

Why Choose Stem Cell Cartilage Regeneration Market Report?

Contact Us:

Worldwide Market Reports, Tel: U.S. +1-415-871-0703 U.K. +44-203-289-4040 Japan +81-50-5539-1737 Email: [emailprotected] Website: https://www.worldwidemarketreports.com/

Read the original here:
Stem Cell Cartilage Regeneration Market Strategic Insights of Developing Industry by Top Growing Prominent Players Profile: Anika Therapeutics, Zimmer...

4 million awarded to University of Sheffield to turn bright ideas into global opportunities – University of Sheffield News

The University of Sheffield has been awarded 4.29 million in funding from UK Research and Innovation (UKRI), to jumpstart the early-stage translation of research that can create real impact for people across the UK.

The University of Sheffield has been awarded 4.29 million in funding from UK Research and Innovation (UKRI), to jumpstart the early-stage translation of research that can create real impact for people across the UK.

The University is one of 64 UK universities and research organisations to be awarded IAA funding and in the top 10 in terms of the highest amounts of funding from UKRIs 118 million pot of IAA funding. The funding will support critical early-stage translation of UK research, knowledge exchange, translation and commercialisation.

IAA funding drives economic growth and attracts private investment, allowing research to be turned into reality through the development of new technologies. It also supports evidence-based policymaking to transform public services, create new jobs, and forge new partnerships with business and charities.

The programme empowers organisations to respond to emerging global opportunities and has provided early-stage support to projects that are now established global businesses.

IAA funding has supported successful knowledge exchange projects at the University of Sheffield for more than 10 years, including:

Vice-President for Innovation at the University of Sheffield, Professor Dave Petley, said: For the University, our innovation and knowledge exchange activities are vital to meeting the challenges society faces, whether this is generating economic prosperity through spin-outs and new ventures, establishing collaborations with our regional partners to improve health and patient care or delivering projects to tackle societal and sustainability challenges.

The University has a strong ambition to drive innovation through knowledge exchange with our partners. Just one example is the development of innovative start-ups and spin-outs through Northern Gritstone, a company created jointly with the Universities of Manchester and Leeds to invest in our spin-out companies.

Last month, Northern Gritstone announced a first close of 215 million, which will lead to investments across emerging sectors such as advanced materials, health technology, cognitive computation and AI in northern England.

UKRI Director of Commercialisation Tony Soteriou, said: The UK is home to some of the brightest, most innovative and creative research teams in the world. They have the ideas and they have the entrepreneurial energy to create businesses and services that could turn sectors on their head.

What they need, what every great commercial idea needs, is support in the critical early stages. The Impact Acceleration Account is the catalyst that allows projects to grow to the next level, attracting investment, forging partnerships and creating jobs.

The breadth of UKRI allows us to work right across the UKs world-class research and innovation system to ensure it builds a green future, secures better health, ageing and wellbeing, tackles infections, and builds a secure and resilient world."

UKRI Chief Executive Professor Dame Ottoline Leyser, said: "Research and innovation has the potential to improve peoples lives and livelihoods, rejuvenating communities across the UK and tackling global challenges. It is imperative that we harness that potential.

The path between discovery and impact is not simple and so it is vital that we provide flexible support that allows talented people and teams, and world-class institutions to connect discovery to prosperity and public good.

Our impact acceleration funding has a fantastic track-record in providing support that helps brilliant ideas become realities that make a real difference.

Go here to read the rest:
4 million awarded to University of Sheffield to turn bright ideas into global opportunities - University of Sheffield News

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting – GuruFocus.com

Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22

TCR directed to a novel C*07:02-restricted epitope of MAGEA1, TSC-204-C07, on track for IND submission in 2H22

Multiplexing TCRs in vitro leads to cytotoxicity of target cell lines and cytokine-mediated enhancement of anti-tumor activity of specific TCR cells

ImmunoBank enables customized multiplexing of TCRs across both targets and HLA restrictions

Hosting virtual KOL event May 19, 2022 at 4:30 p.m. ET to share preclinical data highlights

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, presented two posters and an oral presentation around TScans proprietary platform technologies for its solid tumor program at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

The initial preclinical data on our solid tumor program presented at ASGCT demonstrate the capability of TScans proprietary platforms to identify novel TCRs. Through ReceptorScan, we identified TSC-200-A02 that targets an HLA-A*02:01 restricted epitope of HPV16-E7 and with TargetScan we identified TSC-204-C07 targeting a novel HLA-C*07:02 restricted epitope of MAGE-A1. We are excited to report initial preclinical results, which showed strong cytoxicity of TSC-200-A02 in HPV+ target cell lines and no off-target activity. When we multiplexed the two TCRs in vitro, we were excited to see synergistic cytotoxic activity. said Gavin MacBeath, Ph.D., Chief Scientific Officer.

Dr. MacBeath continued, We are on track to continue progressing IND-enabling studies for the TSC-200 series and submitting IND applications for TSC-200-A02 and TSC-204-C7 during the second half of this year. These initial preclinical results suggest that multiplexing TCRs has the potential to overcome both tumor antigen heterogeneity and HLA loss-of-heterozygosity (LOH).

Presentation Highlights:

Poster presentation titled Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors, presented by Gavin MacBeath, Ph.D.

Poster presentation titled Multiplexed TCR-T cell therapy: A strategy to enhance the efficacy of engineered T cell therapy, presented by Gavin MacBeath, Ph.D.

Oral presentation titled Discovery of a novel C*07:02-restriced epitope on MAGE-A1 and pre-clinical development of an enhanced TCR-T cell therapy candidate for the treatment of solid tumors, presented by Gavin MacBeath, Ph.D.

A copy of the presentation materials can be accessed on the Events and Presentations section of the Companys Investor Relations website at http://www.ir.tscan.com.

Virtual KOL Event

The Company is hosting a virtual KOL event today, Thursday, May 19, 2022, at 4:30 p.m. ET, featuring Kai Wucherpfennig, M.D., Ph.D. Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Womens Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard. The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScans approach to potentially overcome antigen heterogeneity and HLA loss with multiplexed TCR-T. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to [emailprotected]. Registration for the live event can be found here. A replay will be available on the Events and Presentations section of the Companys website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Companys lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Companys bank of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with various types of solid tumors.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding current and future research and development plans or expectations, the structure, timing and success of the Companys planned preclinical development, submission of INDs, and clinical trials, the potential benefits of any of the Companys proprietary platforms or current or future product candidates in treating patients, and the Companys goals, strategy, business plans and focus, among other things. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design, estimate, predict, potential, plan, on track, or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScans TCR-T therapy candidates; TScans expectations regarding its preclinical studies being predictive of clinical trial results; the timing of the initiation, progress and expected results of TScans preclinical studies, clinical trials and its research and development programs; TScans plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScans TCR-T therapy candidates; TScans manufacturing capabilities and the scalable nature of its manufacturing process; TScans estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScans expectations regarding competition; TScans anticipated growth strategies; TScans ability to attract or retain key personnel; TScans ability to establish and maintain development partnerships and collaborations; TScans expectations regarding federal, state and foreign regulatory requirements; TScans ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScans existing capital resources to fund its future operating expenses and capital expenditure requirements; and the effect of the COVID-19 pandemic, including mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScans business or operations; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of TScans Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 9, 2022 and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScans views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Contacts

Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 [emailprotected]

Joyce Allaire LifeSci Advisors, LLC Managing Director 617-435-6602 [emailprotected]

More:
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting - GuruFocus.com